Your European market access agency.
Experience in rare genetic disorders, infectious diseases, neuroscience, oncology, cardio-metabolic etc
Present in all 4 major European markets
4 principal consultants with over 100 years industry experience
>$12bn in deal value in last 12 months for acquisitions of AESARA-supported products
We help you answer key business questions such as:
How can we get our product reimbursed in Europe?
What evidence do we need to show value in Europe?
How do we get through European HTA?
How can our drug get a good price in Europe?
What should we invest in Europe – and when?
We stay ahead of HTA policy and reimbursement trends to help innovator biotechs succeed in European markets.
AESARA deploys deep experience across major European markets to help biotech innovators define evidence-based, realistic and competitive European product access strategy, tailored to the client’s needs.
AESARA’s blend of experienced HTA strategists and access-oriented management consultants can get your company ready for this major change to bringing innovative medicines to market in Europe.
AESARA brings deep price, access and reimbursement expertise to generate trustworthy and digestible reports, enabling biopharma business leaders to quickly assess value potential in assets of interest.
AESARA maintains a continually refreshed network of European HTA, payer and physician advisors, with whom we can quickly and efficiently conduct deep, insightful and effective qualitative value research.
AESARA combines professional services quality and standards, with value & access lived experience, to design practical and effective organisation structures, business processes and internal communications & training.
We are a unique blend of industry veteran access strategists; value evidence scientists; and creative graphic designers.
Our accumulated experience enables us to provide actionable insights and deliver results that align with your strategies.
© 2023 All Rights Reserved.